CD274 and metastatic melanoma: Intracranial response rates were 16 of 35 (46%) in cohort A, five of 25 (20%) in cohort B, and one of 16 (6%) in cohort C. Median OS was not yet reached in cohort A, was 18.5 months in B, and was 5.1 months in C. Median intracranial PFS was not reached in cohort A, was 2.5 months in B, and was 2.3 months in C. Overall, the anti-PD-1/PD-L1 antibodies, nivolumab and pembrolizumab, appear to be effective in treating intracranial manifestations of metastatic melanoma; pembrolizumab may also be efficacious in managing NSCLC BM.